Start:
August 12, 2020
End:
April 2024
Enrollment:
168
Photobiomodulation is a therapy that uses red or near-infrared light to stimulate tissue that has either been injured or is degenerating. This study will test whether stimulation through the nose and the scalp can enhance cognition in older adults at increased risk for Alzheimer's disease. Participants will be randomly assigned to receive either photobiomodulation or a sham treatment. Over 12 weeks, all participants will attend 16 clinic visits (90 minutes each) to receive treatment and will also complete 44 treatments of intranasal stimulation at home (25 minutes each). Researchers will measure changes in cognition and memory using an online computer test and will assess changes in brain energy use and neural connections with MRI brain scans. All assessments will be done at study start, after 12 weeks, and at a three-month follow-up visit.
Minimum Age: 65 Years
Maximum Age: 89 Years
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Arizona | |
---|---|
University of Arizona
Tucson,
AZ
85721
Not yet recruiting
| |
Florida | |
University of Florida McKnight Brain Institute
Gainesville,
FL
32610
Recruiting
Adam J. Woods, PhD |
Lead: University of Florida
Collaborator Sponsor
Source: ClinicalTrials.gov ID: NCT04018092
An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health